MS Pharma Group, a regional pharmaceutical leader operating across the Middle East and North Africa, has entered into an exclusive partnership with global drug manufacturer Hetero Group to localize five well established biosimilar medicines. The agreement focuses on key treatment areas such as oncology, immunology, and hematology and aims to expand access to advanced biologic therapies within Algeria and the wider region.
Health Technology Insights: Cone Health Announces New CEO
The collaboration will be carried out through El Kendi, MS Pharma Group’s Algerian affiliate, together with Hetero Biopharma, a dedicated subsidiary of Hetero Group. This partnership represents Hetero’s first locally based collaboration in Algeria and signals an important step toward strengthening the country’s biopharmaceutical capabilities. The biosimilars included in the agreement represent a combined market value of approximately forty five million US dollars in Algeria based on 2024 estimates. Implementation will follow a localization strategy supported by structured technology transfer to build sustainable manufacturing and supply capacity.
Health Technology Insights: AHN Offers Innovative Low-Dose Radiation Therapy for Osteoarthritis
Kalle Känd, Chief Executive Officer of MS Pharma Group, said the company values working with a global partner that shares a long term vision for knowledge sharing and improved patient outcomes. He explained that the agreement aligns with MS Pharma Group’s mission to broaden access to reliable and affordable biologic medicines while reinforcing local healthcare systems. According to Känd, partnerships of this nature help develop lasting regional expertise and deliver meaningful benefits to both patients and national health infrastructures across the MENA region.
Dr. Vamsi Krishna, Managing Director of Hetero Group, highlighted that access to high quality and affordable medicines remains central to Hetero’s global strategy. He noted that collaborating with MS Pharma Group, a well respected healthcare organization in the Middle East, supports the company’s goal of addressing unmet medical needs in Algeria and other priority markets. He added that the partnership reflects a shared commitment to improving healthcare delivery and expanding the availability of critical therapies.
Together, MS Pharma Group and Hetero Group aim to advance biosimilar adoption through local production, technical expertise, and long term collaboration. The agreement is expected to contribute to greater treatment availability, enhanced healthcare resilience, and continued growth of the biopharmaceutical sector in Algeria and beyond.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 24 December 2025
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
